English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Vitamin D analogues are in clinical use for prevention and treatment of secondary hyperparathyroidism (HPT) in chronic renal failure. Despite recent advances there is a need for vitamin D derivatives with maintained parathyroid hormone suppressive activity and less hypercalcemic and hyperphosphatemic toxicity. Here we show coincident increased expression of the vitamin D activating enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) and reduced expressions of the 1,25(OH)(2)D(3) catabolizing enzyme 25-hydroxyvitamin D(3) 1alpha-hydroxylase (1alpha-hydroxylase) in the majority of investigated parathyroid adenomas and secondary hyperplastic glands. In addition, this relationship was found for the mitochondrial CYP27A enzyme (25-hydroxylase), a potential physiological vitamin D(3) 25-hydroxylase. These findings should be considered in future development of vitamin D analogues for treatment of HPT.

the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism

Increased 25-Hydroxyvitamin D<sub>3</sub>1α-Hydroxylase and Reduced 25-Hydroxyvitamin D<sub>3</sub>24-Hydroxylase Expression in Parathyroid Tumors: New Prospects for Treatment of Hyperparathyroidism with Vitamin D

Increased 25-Hydroxyvitamin D31α-Hydroxylase and Reduced 25-Hydroxyvitamin D324-Hydroxylase Expression in Parathyroid Tumors: New Prospects for Treatment of Hyperparathyroidism with Vitamin D

Increased 25-Hydroxyvitamin D₃1α-Hydroxylase and Reduced 25-Hydroxyvitamin D₃24-Hydroxylase Expression in Parathyroid Tumors: New Prospects for Treatment of Hyperparathyroidism with Vitamin D